Advertisement

Topics

Latest "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Stories

08:03 EDT 25th June 2017 | BioPortfolio

Here are the most relevant search results for "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" found in our extensive news archives from over 250 global news sources.

More Information about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine for you to read. Along with our medical data and news we also list autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Clinical Trials, which are updated daily. BioPortfolio also has a large database of autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Companies for you to search.

Showing "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Articles 1–25 of 13,000+

Extremely Relevant

Research shows how protein component of Epstein-Barr virus promotes development of cancer

After an infection with the Epstein-Barr virus (EBV), the virus persists in the body throughout a person's lifetime, usually without causing any symptoms.


Epstein-Barr virus and cancer: New tricks from an old dog

(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) Approximately 98 percent of all adults are infected with the Epstein-Barr virus. In rare cases, an infection with this virus causes cancer. Scientists at the German Cancer Research Center (DKFZ), at the German Center for Infection Research (DZIF), and at the French Inserm have now discovered that a component of the Epstein-B...

T Cells Targeting Epstein-Barr Virus -- A New Treatment for MS?

This new approach -- based on the theory that the Epstein-Barr virus plays a causative role in MS -- has shown encouraging results in a preliminary study. Medscape Medical News


Epstein-Barr virus steers B-cells to hide in plain sight

Viruses are notorious for taking over their host's operations and using them to their own advantage. But few human viruses make themselves quite as cozy as the Epstein-Barr virus, which can be found in an estimated nine out of ten humans without causing...

Researchers show how Epstein-Barr virus manages to persist inside immune system's B cells

Viruses are notorious for taking over their host's operations and using them to their own advantage. But few human viruses make themselves quite as cozy as the Epstein-Barr virus, which can be found in an estimated nine out of ten humans without causing any ill effects.

Researchers Apply New Immune Technologies in Search of Mono Vaccine

Researchers are analyzing the genetics of human immune responses to develop the basis of an effective vaccine or drug therapy against Epstein-Barr Virus, or EBV

Cancer-causing virus masters cell's replication, immortality

(Duke University) Duke researchers detail how the Epstein-Barr virus manages to persist quietly inside the immune system's B cells in as many as 90 percent of adults. Should something go awry however, the virus can cause mononucleosis or cancers of the lymph. 'The challenge is that it's a really efficient pathogen,' said Micah Luftig, an associate professor of molecular genetics and microbiology.

Cell Medica Raises £60M for Phase II T-Cell Product and Cell Immunotherapy Pipeline

Cell Medica raised $60 million in a Series C round of financing to support development of its cell-based immunotherapy platforms and pipeline, including lead mid-stage oncology candidate, baltaleucel-T (CMD-003). The autologous T-cell therapy is being evaluated in the Phase II CITADEL study and the CIVIC trial, as a treatment for advanced lymphomas associated with Epstein Barr virus (EBV). Par...

Series C round brings £60mm to Cell Medica

Cell Medica Ltd. (cellular immunotherapy) raised £60mm ($73.2mm) through its Series C round from returning investors Touchst...

Epstein-Barr Virus in Pediatric Patients With Acute B-ALL

What role might regulatory T cells and EBV infection play in the pathogenesis of childhood acute B lymphoblastic leukemia? Journal of Clinical Pathology

Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes

Monocytes/macrophages are activated in several autoimmune diseases, including systemic sclerosis (scleroderma; SSc), with increased expression of interferon (IFN)-regulatory genes and inflammatory cytokines, s...

More evidence that Zika mRNA vaccines can stop viral replication in mice

(Cell Press) Vaccine developers have successfully protected mice against Zika by injecting synthetic messenger RNA that encodes for virus proteins into the animals. The cells of the mice then build parts of the virus, training the immune system to recognize a future infection. The research, published Feb. 17 in Cell, follows a Feb. 2 Letter in Nature (doi:10.1038/nature21428) that showed similar p...

Powerful Zika Vaccine Protects Mice and Monkeys from the Virus

(New Scientist) – A new vaccine against Zika virus gives mice and monkeys immunity in tests. The vaccine is based on the inactivated virus, and just one low dose is needed. “The critical difference between ours and everybody else’s is … Read More

Cell-Based Flu Vaccine Hits Commercial Scale

Rather than rely on poultry and the eggs they produce for the manufacture of yearly flu vaccines, the World Health Organization (WHO) and FDA have encouraged vaccine manufacturers to look to other manufacturing technologies, such as use of a cell-based production model. Seqirus announced on June 21, 2017 that it has successfully used such a model for the large-scale production of the flu vaccine u...

Five HIV patients are ‘virus and drug free’ and no longer infectious after two doses of new vaccine – The Sun

The SunFive HIV patients are 'virus and drug free' and no longer infectious after two doses of new vaccineThe SunFIVE people with HIV are 'virus free' after receiving two doses of an experimental new vaccine, scientists have revealed. The participants no longer infectious and don't need to take daily medication to keep the virus at bay. Five people with HIV are ...How Uganda got results in its fig...

NIH respiratory syncytial virus vaccine enters clinical testing

A phase I clinical trial to test the safety and tolerability of an investigational vaccine against respiratory syncytial virus (RSV) has begun at the NIH Clinical Center in Bethesda, Maryland. The trial will also assess the vaccine’s ability to prompt an immune response in healthy adult participants. The investigational vaccine was developed by scientists at […] The post NIH respiratory sy...

Pending EC decision: Zulvac BTV Ovis, bluetongue virus vaccine, serotype 1 (inactivated) / bluetongue virus vaccine, serotype 4 (inactivated) / bluetongue virus vaccine, serotype 8 (inactivated) / bluetongue virus vaccine, serotype 8 (inactivated), Opini

Make the Diagnosis: Extremity Dilemma

(MedPage Today) -- Case Findings: The mother of a 3-year-old brought her daughter to the pediatrician when she developed a rash of smooth papules across her buttocks that spread outward to her arms and down her legs. It barely appeared on her trunk. She complained that it was itchy and had a fever and enlarged lymph nodes. Just a short time before the rash appeared, the mother reported that her da...

Cuba begins Phase 1 testing of HIV vaccine

Cuba has announced that it has begun testing a HIV vaccine that looks to reduce the ‘payload’ of the virus within the patients. The study will examine a small number of patients to determine the safety of the vaccine. Previous pre-clinical trials in animals and small studies involving humans have found that the vaccine boosted the immune response to the virus whilst not displaying any adverse ...

Outcome of third salvage autologous stem cell transplantation in multiple myeloma

Dr Garderet speaks with ecancer at the 16th International Myeloma Workshop about the outcome of third salvage autologous stem cell transplantation in multiple myeloma. Autologous stem cell transplantation remains a standard treatment for younger...

Potential Zika virus vaccine

Preclinical research results in animal models demonstrate favorable outcomes in developing a vaccine against the mosquito-borne Zika virus.

Investigational Vaccine Protected Monkeys from HIV-Like Virus

The vaccine adds three more targets to a human vaccine candidate that showed promise

More-is-better approach appears to improve vaccine protection from HIV-like virus in monkeys

Building on insights from an HIV vaccine regimen in humans that had partial success during a phase 3 clinical trial in Thailand, a Duke-led research team used a more-is-better approach in monkeys that appeared to improve vaccine protection from an HIV-like virus.

New Polio Virus Evolution Insights Could Lead to Improved Vaccine

NewsThe polio virus used the same three evolutionary steps to evolve from harmless vaccine into a regional menace.

Promising Preclinical Results of Zika Virus Vaccine

NewsCCNY, TechnoVax translational research leads to potential Zika virus vaccine.


Quick Search
Advertisement
 

News Quicklinks